神经节苷脂治疗新生儿缺氧缺血性脑病的疗效分析及对血清IL-23、IL-17水平的影响

Curative Effect Analysis of Neonatal Hypoxic-ischemic Encephalopathy Treated with Ganglioside and Its Influence of Serum IL-23 and IL-17 Levels

目的:观察神经节苷脂治疗新生儿缺氧缺血性脑病(HIE)的疗效及对血清白介素-23(IL-23)、白介素-17(IL-17)水平的影响,为临床应用神经节苷脂治疗HIE提供依据。方法:将84例HIE患儿分为对照组(n=42)和观察组(n=42),对照组采用常规治疗,观察组在此基础上加用神经节苷脂,比较两组患儿总有效率、反射恢复时间、肌张力恢复时间、意识恢复时间,于治疗前、后提取血清,应用酶联免疫吸附法(ELISA)检测血清IL-23与IL-17水平。结果:观察组患儿总有效率高于对照组(P<0.05),反射恢复时间、肌张力恢复时间、意识恢复时间短于对照组(P<0.05);两组患儿治疗后血清IL-23、IL-17水平均较治疗前降低(P<0.05),而且观察组治疗后血清IL-23、IL-17水平低于同期对照组(P<0.05)。结论:神经节苷脂治疗HIE疗效显著,抑制IL-23/IL-17炎症轴可能是神经节苷脂治疗HIE的重要机制之一。

Objective： To explore the effect of Ganglioside in the treatment of neonatal hypoxic-ischemic encephalopathy（HIE） and the influence of interleukin-23（IL-23） and interleukin-17（IL-17） levels, thereby to provide the basis for application of ganglioside to treat HIE.Method： 84 cases with HIE were randomly divided into the control group（n=42） and the observation group（n=42）.The control group were treated with conventional therapy.On the basis of this, the observation group were administrated with Ganglioside.Total effective rate, reflection recovery time, muscle tonus recovery time, and consciousness recovery time were compared between the observation group and the control group.Serum was isolated before and after treatment, enzyme linked immunosorbent assay（ELISA） was then used to detect serum IL-23 and IL-17 levels.Result： In comparison with control group, a significant increase in total effective rate and a significant decrease in reflection recovery time, muscle tonus recovery time and consciousness recovery time in observation group.There were statistical significance（P〈O.05）.Serum IL-23 and IL-17 levels were lower after treatment than before treatment in two group （P〈0.05）.Moreover, Serum IL-23 and IL-17 levels were also significantly decreased after treatment in observation group when compared with same period in the control group（P〈0.05）.Conelusion： Treatment of HIE with Ganglioside has good curative effects.Inhibition of the IL-23/IL-17 inflammatory axis may be one of significant mechanisms by which Ganglioside treats HIE.